Physician profile
Robin E Hauck
NPI 1043445745
$2,060.04
in general payments reported to CMS, 2019-2025
19 companies · $552 in 2025
The $552 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $98.07 · 2021: $212 · 2022: $306 · 2023: $299 · 2024: $460 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.44 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $434.74 | 2023-2025 | Cequa |
| Coopervision INC. | $246.12 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $243.54 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $221.37 | 2020-2025 | Precision7, Total30, Rocklatan |
| Novartis Pharmaceuticals Corporation | $179.73 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $119.65 | 2021-2023 | Tobradex St |
| Johnson & Johnson Vision Care, INC. | $86.86 | 2021-2025 | |
| Oyster Point Pharma, INC. | $82.15 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $67.67 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.14 | 2019-2021 | |
| Allergan, INC. | $55.15 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $53.35 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $45.64 | 2024 | Idose |
| Aerie Pharmaceuticals, INC. | $44.82 | 2019-2021 | |
| Harrow Eye, LLC | $34.83 | 2024-2025 | Vevye, Iheezo, Triesence |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33.64 | 2025 | |
| Biotissue Holdings INC. | $20.35 | 2024 | |
| Dompe US, INC. | $17.99 | 2024 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $16.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Hauck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.